Duke-Margolis Institute for Health Policy’s Post

While prescription drug promotion can provide you with valuable information, it’s important it is truthful and not misleading. Learn more about prescription drug promotion and FDA’s Bad Ad Program: http://www.fda.gov/BadAd #FDABadAd

New on our blog, our team takes a deep dive into the House Committee's new report on prescription drug prices and how it could ultimately impact medication costs: https://lnkd.in/edXysS3V

Over the last year, interest in weight loss solutions have been all the roar. This trending drug interest is causing the U.S. prescription drug spending to increase by over 13.5%. To learn more about this rise, check out this article https://bit.ly/4dSGzU0

Webinar: Navigating the “Clear, Conspicuous, and Neutral” DTC Prescription Drug Ad Final Rule for Agencies 📅 DATE: Wednesday, April 10 ⏰ TIME: 1:00 pm ET Starting May 20, the FDA's new rule on direct-to-consumer prescription drug ads takes effect. It mandates the communication of major side effects and contraindications in what's termed a "clear, conspicuous, and neutral manner" (CCN). The days of speed-read, technical jargon disclaimers jammed in the last few seconds of Rx ads are now a thing of the past. Health and pharma marketers, prepare to start using consumer-friendly, readily understandable language. Learn more in this deep-dive conversation between: - Suzanna Boyle, Regulatory Council, Office of Medical Policy, Office of Prescription Drug Promotion @ U.S. Food and Drug Administration - James Potter, Executive Director Coalition for Healthcare Communication of Healthcare Communication 🔗 Register here: https://bit.ly/3VL6u9l #healthcaremarketing #prescriptiondrugmarketing #pharmamarketing #pharmaceuticalmarketing

For those that do not understand why prescription drug cost are so high, this is a good read to start with. A few Key Points: - THE U.S. PAYS 2X-4X MORE FOR BRAND NAME DRUGS THAN OTHER COUNTRIES. In 2021, the Government Accountability Office released an analysis of prices of 20 brand-name drugs in the U.S., Canada, Australia, and France. The study found that retail prices were more than two to four times as high as in the U.S. "As a result, the actual differences between U.S. prices and those of the other countries were likely larger than GAO estimates," the report said. - FDA APPROVAL - WHAT DOES IT REALLY MEAN? If the FDA grants an approval, it means the agency has determined that the benefits of the product outweigh the risks for the intended use. Many Americans believe the approval means something more. Many other countries approve new prescription drugs based in efficacy, “ . . . Many nations conduct public cost-benefit analyses on new drugs, comparing them with others on the market. If those studies find the cost is too high, or the health benefit too low, they'll reject the drug application.” This difference allows Pharma to develop alternate drugs to those already on the market with a proven history, and often generic status, then advertise them as the greatest thing since sliced bread and charge astronomical prices for a drug that is often equal to or less effective than a much cheaper drug that's been available for years. - BIG PHARMA USES ANTI-COMPETITIVE BUSINESS TACTICS TO MAINTAIN HIGH PRICES.: "Drug patents and exclusivity is another factor keeping U.S. drug prices higher, experts said, as U.S. pharmaceutical companies have amassed patents to prevent generic competitors from bringing cheaper versions to market." - HIGH PRICES ARE NECESSARY TO FUND R&D, according to Big Pharma. This is an argument we've heard for years. I first called BS on this back in the early 2000s when I saw a report that showed that Pharma's advertising spend was approx. $4.3Bil versus R&D at the time of approx. $1.3Bil. "One 2023 study found that from 1999 to 2018, the world's largest 15 bio-pharmaceutical companies spent more on selling and general and administrative activities, which include marketing, than on research and development. The study also said MOST NEW MEDICINES DEVELOPED DURING THIS PERIOD OFFERED LITTLE TO NO CLINICAL BENEFIT OVER EXISTING TREATMENTS."

🚨 Major Update to Drug Ads! 🚨 New federal rule increases transparency in drug commercials. Expect clearer explanations of side effects and usage guidelines—no more confusing rapid-fire disclaimers! 🔍 Why it matters? This could revolutionize how we understand and approach prescription drugs. Read more about the changes and their impact here: https://lnkd.in/e2EhTdMW

Prescription medications for treating complex and chronic neurologic conditions, such as multiple sclerosis, have become increasingly expensive over the years. One drug that hit the market in 1996 has seen a staggering 825% price increase, while another drug that was introduced in 2003 has seen its price soar by 4,319%. This situation calls for urgent action to ensure that patients have access to affordable and effective medications. #healthcare #prescriptiondrugs #drugprices #healthcarereform #neurology #neurologicaldisorders #multiplesclerosis

Understanding the New FDA Rules for Prescription Drug Ads 📺💊 https://hubs.la/Q02RC_z10 New FDA regulations are changing the way prescription drug ads are presented on TV and radio—effective November 20, 2024. These rules require clear, simultaneous presentation of risks in both audio and text, ensuring viewers fully understand the benefits and risks. 📣📝 From clear language to balanced audio and readable text, it’s essential to update ads to comply with the new requirements. These changes apply to all ads—old and new—so the time to prepare is now. Dive into our article to understand these updates and how to stay compliant with the latest standards. 👩⚕️👨⚕️ 🔗https://hubs.la/Q02RC_z10

AWP is one of the drug supply chain industry’s dirty little secrets about prescription drug pricing. Our pharmacist explains. Call us today (724) 246-6257 to find out the real cost of your medication. #costplus #pharmacy #NewBrightonPA #BeaverCountyPA

Heading out to the annual conference for NCPDP (National Council for Prescription Drug Programs, Inc.) this morning! Looking forward to hearing more about what our #pharmacy partners are dealing with each day and how we can work together towards solutions. If you are in Scottsdale this week, send me a message so we can connect and collaborate! #inmarjourney #theyearoftheproduct #NCPDP24